Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals has 1,381 announcements on record, routine notices left out; 3 in the 30 days to 31 Oct 2026, the latest on 23 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Glenmark Pharmaceuticals quarterly results
Nov5Thu
The board meets on 5 Nov 2026 to consider financial results
Notice filed 23 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Glenmark Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Glenmark Pharmaceuticals financials, year by year
Annual reports17
- Annual report, year to Mar 202613 Aug 2026
- Annual report, year to Mar 202529 Aug 2025
- Annual report, year to Mar 20243 Sep 2024
- Annual report, year to Mar 20234 Sep 2023, a zip file
- Annual report, year to Mar 202227 Aug 2022, a zip file
12 earlier reports
- Annual report, year to Mar 202127 Aug 2021, a zip file
- Annual report, year to Mar 20204 Sep 2020, a zip file
- Annual report, year to Mar 20193 Sep 2019, a zip file
- Annual report, year to Mar 20183 Oct 2018, a zip file
- Annual report, year to Mar 20174 Oct 2017, a zip file
- Annual report, year to Mar 201619 Aug 2016, a zip file
- Annual report, year to Mar 201529 Aug 2015, a zip file
- Annual report, year to Mar 201430 Jun 2014, a zip file
- Annual report, year to Mar 20135 Jul 2013, a zip file
- Annual report, year to Mar 201210 Jul 2012, a zip file
- Annual report, year to Mar 201120 Jun 2012, a zip file
- Annual report, year to Mar 20103 Sep 2010, a zip file
Investor presentations26
- Investor Presentation31 Jul 2026
- Investor Presentation9 Jun 2026
- Investor Presentation29 May 2026
- Investor Presentation30 Jan 2026
- Investor Presentation14 Nov 2025
21 earlier presentations
- Investor Presentation14 Aug 2025
- Presentation16 Jul 2025
- Investor Presentation23 May 2025
- Investor Presentation14 Feb 2025
- Investor Presentation14 Nov 2024
- Investor Presentation14 Aug 2024
- Investor Presentation30 May 2024
- Investor Presentation24 May 2024
- Investor Presentation14 Feb 2024
- Investor Presentation10 Nov 2023
- Investor Presentation21 Sep 2023
- Investor Presentation19 May 2023
- Investor Presentation10 Feb 2023
- Further to our communication dated November 11, 2022, attached is a copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2022 which is scheduled today at 17:30 IST, in Mumbai. Kindly take the same on record and acknowledge receipt.17 Nov 2022
- Presentation that will be made at the J. P. Morgan Healthcare Conference, San Francisco, USA,.10 Jan 2017, a zip file
- Presentation on Strategic Blueprint for the Next Decade to be presented today at Analyst and Investor Meet 2016.19 Dec 2016, a zip file
- Investor Presentation19 Jul 2016, a zip file
- Investor Presentation of the Company at J P Morgan Healthcare Conference January 201612 Jan 2016, a zip file
- Investor Presentation of the Company at J P Morgan Healthcare Conference in San Francisco, USA.14 Jan 2015, a zip file
- The "Investor Presentation made by the Company at the JP Morgan Healthcare Conference on Jan, 12, 2012 in San Frabcisco, USA".13 Jan 2012, a zip file
- Analysts Presentation.16 May 2011, a zip file
Earnings calls40
- Transcript5 Aug 2026
- Link of Recording3 Aug 2026
- Transcript of the Earnings call has been uploaded on Company's website5 Jun 2026
- Link of Recording1 Jun 2026
- Transcript4 Feb 2026
35 earlier call documents
- Link of Recording2 Feb 2026
- Enclosed please find herewith the details of Earnings Call slated for Monday, February 02, 2026 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording ....22 Jan 2026
- Transcript19 Nov 2025
- Link of Recording17 Nov 2025
- Enclosed please find herewith the details of Earnings Call slated for Monday, November 17, 2025 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording ....6 Nov 2025
- Transcript28 Aug 2025
- Audio Recording of Investor Day 2025 held on 16th July, 2025.23 Jul 2025
- Transcript27 May 2025
- Link of Recording26 May 2025
- Enclosed please find herewith the details of Earnings Call slated for Monday, May 26, 2025 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording ....19 May 2025
- Transcript19 Feb 2025
- Link of Recording17 Feb 2025
- Transcript21 Nov 2024
- Link of Recording18 Nov 2024
- Transcript20 Aug 2024
- Link of Recording16 Aug 2024
- Transcript of Investor Day 20244 Jun 2024
- Transcript29 May 2024
- Link of Recording27 May 2024
- Transcript19 Feb 2024
- Link of Recording16 Feb 2024
- Transcript20 Nov 2023
- Link of Recording15 Nov 2023
- Transcript21 Aug 2023
- Link of Recording14 Aug 2023
- Transcript25 May 2023
- Link of Recording22 May 2023
- Transcript15 Feb 2023
- Link of Recording13 Feb 2023
- Further to our letter dated 03rd November, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings call held on Monday, November 14, 2022 for the quarter and half year ended September 30, 2022 has been uploaded on the Company's website18 Nov 2022
- Audio recording of Q2 of FY 2022-23 Earnings Call14 Nov 2022
- Further to our letter dated 01st August, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, August 12, 2022 for the quarter ended June 30, 2022 has been uploaded on the Company's website.17 Aug 2022
- Audio recording of Q1 of FY 2022-23 Earnings Call12 Aug 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call3 Jun 2022
- Audio recording of Q4 & FY22 Earnings Call30 May 2022
Glenmark Pharmaceuticals merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings2
- Certified copy of order of the Hon'ble High Court of Judicature at Bombay approving the Scheme of Amalgamation of Glenmark Generics Limited and Glenmark Access Limited with Glenmark Pharmaceuticals Limited are being filed by the respective Companies with the Registrar of Companies, Mumbai, Maharashtra on April 10, 2015. With the filing of the court order with the Registrar of Companies, Glenmark Generics Limited and Glenmark Access Limited would stand dissolved without being wound up and the Scheme would become effective as on April 10, 2015.10 Apr 2015, a zip file
- Board of Directors of Glenmark Pharmaceuticals Ltd., in their meeting held January 31, 2014, have approved a proposal to merge its subsidiaries i.e. Glenmark Generics Ltd. ("GGL") and Glenmark Access Ltd. ( GAL ) with GPL.31 Jan 2014, a zip file
Glenmark Pharmaceuticals share news and announcements
Newest first. Page 1 of 28.
Oct 2026
23 Oct · Analysts
23 Oct · Board meeting
Sep 2026
21 Sep · Analysts
11 Sep · Rating
Aug 2026
10 Aug · Options to purchase securities
7 Aug · Analysts
Jul 2026
31 Jul · Results
21 Jul · Analysts
15 Jul · Board meeting
Jun 2026
30 Jun · General Updates
25 Jun · Analysts
May 2026
29 May · Management
29 May · Results
29 May · Analysts
23 May · Analysts
Apr 2026
30 Apr · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Mar 2026
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 11 Sep 2026Credit ratingup 0.17%+0.5 pts vs Nifty 500market median 0.0% · five sessions +1.3% (+1.8 pts vs Nifty 500) · volume 0.7× usual · delivery +8.0 pts against usual · The announcement
- 3 Aug 2026Resultsdown 0.17%−1.6 pts vs Nifty 500market median −0.7% · five sessions +2.0% (+1.0 pts vs Nifty 500) · volume 2.4× usual · delivery −18.1 pts against usual · The announcement
- 1 Jun 2026Resultsdown 3.24%−2.3 pts vs Nifty 500market median −0.7% · five sessions −4.8% (−3.9 pts vs Nifty 500) · volume 2.6× usual · delivery −26.4 pts against usual · The announcement
- 1 Jun 2026Board or managers changeddown 3.24%−2.3 pts vs Nifty 500market median 0.0% · five sessions −4.8% (−3.9 pts vs Nifty 500) · volume 2.6× usual · delivery −26.4 pts against usual · The announcement
- 1 Feb 2026Resultsdown 3.77%−1.7 pts vs Nifty 500market median −0.7% · five sessions −2.3% (−3.8 pts vs Nifty 500) · volume 0.8× usual · delivery −18.4 pts against usual · The announcement
- 17 Nov 2025Resultsdown 1.41%−1.9 pts vs Nifty 500market median −0.7% · five sessions −2.7% (−2.5 pts vs Nifty 500) · volume 8.2× usual · delivery −14.8 pts against usual · The announcement
- 26 Sep 2025Dividenddown 2.91%−1.6 pts vs Nifty 500market median 0.0% · five sessions −2.5% (−2.5 pts vs Nifty 500) · volume 1.3× usual · delivery −6.7 pts against usual · The announcement
- 19 Sep 2025Credit ratingdown 1.10%−1.0 pts vs Nifty 500market median 0.0% · five sessions −3.7% (−1.6 pts vs Nifty 500) · volume 1.0× usual · delivery +10.0 pts against usual · The announcement
- 18 Aug 2025Resultsdown 3.46%−4.6 pts vs Nifty 500market median −0.7% · five sessions −5.2% (−6.6 pts vs Nifty 500) · volume 1.9× usual · delivery −5.9 pts against usual · The announcement
- 24 Jul 2025Credit ratingup 0.25%+0.8 pts vs Nifty 500market median 0.0% · five sessions +0.7% (+2.4 pts vs Nifty 500) · volume 0.3× usual · delivery +7.7 pts against usual · The announcement
20 earlier announcements
- 23 Jun 2025Board or managers changedup 2.94%+3.1 pts vs Nifty 500market median 0.0% · five sessions +4.6% (+2.0 pts vs Nifty 500) · volume 1.6× usual · delivery −12.1 pts against usual · The announcement
- 26 May 2025Resultsdown 2.12%−2.7 pts vs Nifty 500market median −0.7% · five sessions +2.6% (+2.5 pts vs Nifty 500) · volume 3.5× usual · delivery −13.4 pts against usual · The announcement
- 7 Apr 2025Board or managers changeddown 3.84%−0.5 pts vs Nifty 500market median 0.0% · five sessions −8.2% (−10.5 pts vs Nifty 500) · volume 0.9× usual · delivery −7.3 pts against usual · The announcement
- 27 May 2024Dividendup 8.06%+8.0 pts vs Nifty 500market median 0.0% · five sessions +12.0% (+13.8 pts vs Nifty 500) · volume 12.1× usual · delivery −17.3 pts against usual · The announcement
- 26 Apr 2024Credit ratingdown 0.09%0.0 pts vs Nifty 500market median 0.0% · five sessions −2.5% (−2.9 pts vs Nifty 500) · volume 0.6× usual · delivery −17.1 pts against usual · The announcement
- 21 Mar 2024Credit ratingup 0.57%−0.8 pts vs Nifty 500market median 0.0% · five sessions +1.8% (−1.4 pts vs Nifty 500) · volume 0.6× usual · delivery +5.5 pts against usual · The announcement
- 14 Mar 2024Credit ratingup 4.35%+3.0 pts vs Nifty 500market median 0.0% · five sessions +4.8% (+4.8 pts vs Nifty 500) · volume 0.8× usual · delivery +9.9 pts against usual · The announcement
- 4 Oct 2023Credit ratingdown 4.21%−3.5 pts vs Nifty 500market median 0.0% · five sessions −6.7% (−7.0 pts vs Nifty 500) · volume 0.6× usual · delivery −13.3 pts against usual · The announcement
- 29 Sep 2023Credit ratingup 10.11%+9.4 pts vs Nifty 500market median 0.0% · five sessions +2.1% (+1.4 pts vs Nifty 500) · volume 5.2× usual · delivery −22.9 pts against usual · The announcement
- 25 Sep 2023Credit ratingdown 2.15%−2.2 pts vs Nifty 500market median 0.0% · five sessions +6.6% (+6.4 pts vs Nifty 500) · volume 1.0× usual · delivery −6.5 pts against usual · The announcement
- 22 May 2023Dividenddown 2.93%−3.6 pts vs Nifty 500market median 0.0% · five sessions −5.3% (−7.1 pts vs Nifty 500) · volume 2.7× usual · delivery −1.9 pts against usual · The announcement
- 22 May 2023Board or managers changeddown 2.93%−3.6 pts vs Nifty 500market median 0.0% · five sessions −5.3% (−7.1 pts vs Nifty 500) · volume 2.7× usual · delivery −1.9 pts against usual · The announcement
- 24 Dec 2021Credit ratingdown 1.79%−1.2 pts vs Nifty 500market median 0.0% · five sessions +4.0% (+3.4 pts vs Nifty 500) · volume 0.5× usual · delivery −4.0 pts against usual · The announcement
- 22 Nov 2021Credit ratingdown 2.77%−0.6 pts vs Nifty 500market median 0.0% · five sessions +10.3% (+14.2 pts vs Nifty 500) · volume 1.5× usual · delivery −3.1 pts against usual · The announcement
- 25 Nov 2020Credit ratingdown 2.96%−1.5 pts vs Nifty 500market median 0.0% · five sessions −0.2% (−1.3 pts vs Nifty 500) · volume 0.9× usual · delivery +15.5 pts against usual · The announcement
- 29 Oct 2020Board or managers changeddown 1.89%−1.5 pts vs Nifty 500market median 0.0% · five sessions +3.9% (+2.6 pts vs Nifty 500) · volume 0.8× usual · delivery +9.7 pts against usual · The announcement
- 30 Jul 2020Credit ratingup 4.05%+4.8 pts vs Nifty 500market median 0.0% · five sessions +5.5% (+5.6 pts vs Nifty 500) · volume 3.6× usual · delivery −9.7 pts against usual · The announcement
- 13 Jul 2020Credit ratingdown 2.61%−2.8 pts vs Nifty 500market median 0.0% · five sessions +0.7% (−0.2 pts vs Nifty 500) · volume 0.2× usual · delivery +23.0 pts against usual · The announcement
- 29 Jun 2020Dividendup 0.24%+1.1 pts vs Nifty 500market median 0.0% · five sessions −7.3% (−8.9 pts vs Nifty 500) · volume 1.1× usual · delivery −0.4 pts against usual · The announcement
- 12 Jul 2019Credit ratingup 0.01%+0.1 pts vs Nifty 500market median 0.0% · five sessions −2.3% (−2.2 pts vs Nifty 500) · volume 0.7× usual · delivery −5.8 pts against usual · The announcement
Glenmark Pharmaceuticals results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Revenue from operations | Quarter to Jun 2018 | Standalone | 1,618.41 | 1,405.84 | −13.1% | 11 Aug 2018 | 14 Nov 2018 |
| Other income | Quarter to Jun 2018 | Standalone | 173.65 | 165.56 | −4.7% | 11 Aug 2018 | 14 Nov 2018 |
| Total income | Quarter to Jun 2018 | Standalone | 1,792.06 | 1,571.40 | −12.3% | 11 Aug 2018 | 14 Nov 2018 |
| Materials used | Quarter to Jun 2018 | Standalone | 514.77 | 408.50 | −20.6% | 11 Aug 2018 | 14 Nov 2018 |
| Employee costs | Quarter to Jun 2018 | Standalone | 229.69 | 201.27 | −12.4% | 11 Aug 2018 | 14 Nov 2018 |
| Depreciation and amortisation | Quarter to Jun 2018 | Standalone | 33.42 | 27.31 | −18.3% | 11 Aug 2018 | 14 Nov 2018 |
| Other expenses | Quarter to Jun 2018 | Standalone | 406.20 | 359.83 | −11.4% | 11 Aug 2018 | 14 Nov 2018 |
| Total expenses | Quarter to Jun 2018 | Standalone | 1,296.70 | 1,170.75 | −9.7% | 11 Aug 2018 | 14 Nov 2018 |
| Profit before tax | Quarter to Jun 2018 | Standalone | 495.36 | 400.65 | −19.1% | 11 Aug 2018 | 14 Nov 2018 |
| Tax | Quarter to Jun 2018 | Standalone | 97.97 | 65.64 | −33.0% | 11 Aug 2018 | 14 Nov 2018 |